Abstract:Identifying and refining clinically significant patient stratification is a critical step toward realizing the promise of precision medicine in asthma. Several peripheral blood hallmarks, including total peripheral blood eosinophil count (BEC) and immunoglobulin E (IgE) levels, are routinely used in asthma clinical practice for endotype classification and predicting response to state-of-the-art targeted biologic drugs. However, these biomarkers appear ineffective in predicting treatment outcomes in some patients, and they differ in distribution between racially and ethnically diverse populations, potentially compromising medical care and hindering health equity due to biases in drug eligibility. Here, we propose constructing an unbiased patient stratification score based on DNA methylation (DNAm) and utilizing it to refine the efficacy of hallmark biomarkers for predicting drug response. We developed Phenotype Aware Component Analysis (PACA), a novel contrastive machine-learning method for learning combinations of DNAm sites reflecting biomedically meaningful patient stratifications. Leveraging whole-blood DNAm from Latino (discovery; n=1,016) and African American (replication; n=756) pediatric asthma case-control cohorts, we applied PACA to refine the prediction of bronchodilator response (BDR) to the short-acting β2-agonist albuterol, the most used drug to treat acute bronchospasm worldwide. While BEC and IgE correlate with BDR in the general patient population, our PACA-derived DNAm score renders these biomarkers predictive of drug response only in patients with high DNAm scores. BEC correlates with BDR in patients with upper-quartile DNAm scores (OR 1.12; 95% CI [1.04, 1.22]; P=7.9 e-4) but not in patients with lower-quartile scores (OR 1.05; 95% CI [0.95, 1.17]; P=0.21); and IgE correlates with BDR in above-median (OR for response 1.42; 95% CI [1.24, 1.63]; P=3.9e-7) but not in below-median patients (OR 1.05; 95% CI [0.92, 1.2]; P=0.57). These results hold within the commonly recognized type 2 (T2)-high asthma endotype but not in T2-low patients, suggesting that our DNAm score primarily represents an unknown variation of T2 asthma. Among T2-high patients with high DNAm scores, elevated BEC or IgE also corresponds to baseline clinical presentation that is known to benefit more from biologic treatment, including higher exacerbation scores, higher allergen sensitization, lower BMI, more recent oral corticosteroids prescription, and lower lung function. Our findings suggest that BEC and IgE, the traditional asthma biomarkers of T2-high asthma, are poor biomarkers for millions worldwide. Revisiting existing drug eligibility criteria relying on these biomarkers in asthma medical care may enhance precision and equity in treatment.

Benchmarking omics-based prediction of asthma development in children

Urinary Metabolomic Profiling Reveals Biological Pathways and Predictive Signatures Associated with Childhood Asthma

A Strategy for High-Dimensional Multivariable Analysis Classifies Childhood Asthma Phenotypes from Genetic, Immunological, and Environmental Factors

Omics Approaches: A Useful Tool in Asthma Precision Medicine

Integrating multi-omics data of childhood asthma using a deep association model

Predicting the Risk of Asthma Development in Youth Using Machine Learning Models

Consistent Biomarkers And Related Pathogenesis Underlying Asthma Revealed By Systems Biology Approach

Omics approaches in asthma research: Challenges and opportunities

Early prediction of pediatric asthma in the Canadian Healthy Infant Longitudinal Development (CHILD) birth cohort using machine learning

Identification of candidate genes and molecular mechanisms related to asthma progression using bioinformatics

Utilizing Deep Machine Learning to Disclose Hematological Indices and Biomarkers in Asthma-COPD Overlap

Assessing prospective molecular biomarkers and functional pathways in severe asthma based on a machine learning method and bioinformatics analyses

Exploring the molecular mechanisms of asthma across multiple datasets

Epigenetic patient stratification via contrastive machine learning refines hallmark biomarkers in minoritized children with asthma

Radiomultiomics: quantitative CT clusters of severe asthma associated with multi-omics

Genomic Predictors of Asthma Phenotypes and Treatment Response

An integrated molecular risk score early in life for subsequent childhood asthma risk

Deciphering the Immune Subtypes and Signature Genes: A Novel Approach Towards Diagnosing and Prognosticating Severe Asthma through Interpretable Machine Learning

Deep Multi-Omic Profiling Reveals Molecular Signatures that Underpin Preschool Wheeze and Asthma

The role of artificial intelligence in identifying asthma in pediatric inpatient setting

Predicting asthma control deterioration in children